ArticleBMC public health2025
Time to death and its associated factors among tuberculosis patients undergoing directly observed therapy at Butajira General Hospital: using accelerated failure time model.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Predictors of unsuccessful tuberculosis treatment outcome in Bhutan: A retrospective study using comprehensive national tuberculosis surveillance data.Scientific reports · 2026Article
- Cox Proportional Hazards Model Analysis of Survival Among Tuberculosis Patients Under Treatment in Mbuji-Mayi, Democratic Republic of the Congo.Journal of multidisciplinary healthcare · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTuberculosis (TB) remains a significant public health challenge, especially in resource-limited settings like Ethiopia, where the incidence is estimated at 151 cases per 100,000 population. Delays in diagnosis and treatment contribute substantially to TB-related morbidity and mortality. This study aimed to assess the time to death and identify key risk factors influencing mortality among TB patients receiving directly observed therapy (DOT) at Butajira General Hospital using a parametric survival approach.
methodsA retrospective cohort study was conducted among TB patients treated at Butajira General Hospital between September 2019 and August 2023. Survival analysis techniques including the Kaplan-Meier estimator, stratified Cox proportional hazards model, and the Accelerated Failure Time (AFT) model were employed to estimate survival time and identify factors associated with mortality.
resultsAmong 571 TB patients included in the study, 99 (17.3%) died during the follow-up period. The Weibull AFT model revealed that male sex (Φ = 0.75, 95% CI: 0.60-0.94, p = 0.015), age over 45 years (Φ = 0.70, 95% CI: 0.50-0.95, p = 0.030), HIV co-infection (Φ = 0.50, 95% CI: 0.35-0.72, p < 0.001), smoking (Φ = 0.60, 95% CI: 0.45-0.80, p < 0.001), multidrug-resistant TB, and working outside healthcare facilities (Φ = 0.70, 95% CI: 0.50-0.98, p = 0.040) were associated with accelerated time to death. In contrast, larger family size fewer than three members (Φ = 1.70, 95% CI: 1.20-2.42, p = 0.004) and more than three members (Φ = 2.50, 95% CI: 1.75-3.60, p = 0.001) as well as extrapulmonary TB (Φ = 1.80, 95% CI: 1.30-2.50, p = 0.001), smear-negative pulmonary TB (Φ = 1.60, 95% CI: 1.20-2.20, p = 0.005), and baseline weight over 35 kg (Φ = 1.90, 95% CI: 1.40-2.60, p < 0.001) were associated with longer survival time.
conclusionThis study identified several significant predictors of TB-related mortality. Male sex, older age, HIV co-infection, smoking, multidrug-resistant TB (MDR-TB), and employment outside healthcare settings were associated with accelerated time to death. In contrast, better nutritional status, larger family support, and non-smear-positive TB types were linked to longer survival. The TB/HIV co-infection rate observed in this cohort exceeded the national average, highlighting the need for strengthened and integrated TB/HIV care. These findings can guide healthcare strategies, emphasizing the need for targeted interventions for high-risk groups and improving social support and healthcare access to enhance patient outcomes in TB management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.